Focused On-demand Library for Sphingosine 1-phosphate receptor 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q99500

UPID:

S1PR3_HUMAN

Alternative names:

Endothelial differentiation G-protein coupled receptor 3; Sphingosine 1-phosphate receptor Edg-3

Alternative UPACC:

Q99500; Q5SQD8; Q7Z5I2

Background:

Sphingosine 1-phosphate receptor 3 (S1P3), also known as Endothelial differentiation G-protein coupled receptor 3, plays a pivotal role in mediating cellular processes. It functions as a receptor for sphingosine 1-phosphate (S1P), a lysosphingolipid that influences cell proliferation, suppression of apoptosis, and various physiological effects across tissues.

Therapeutic significance:

Understanding the role of Sphingosine 1-phosphate receptor 3 could open doors to potential therapeutic strategies. Its involvement in critical cellular functions highlights its potential as a target for drug discovery, aiming to modulate cell proliferation and survival pathways.